Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours.

Serrano C, Simonetti S, Hernández-Losa J, Valverde C, Carrato C, Bagué S, Orellana R, Somoza R, Moliné T, Carles J, Huguet P, Romagosa C, Ramón y Cajal S.

Histopathology. 2013 Feb;62(3):499-504. doi: 10.1111/his.12021. Epub 2012 Nov 27.

PMID:
23190154
2.

Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.

de Vries M, Bruijn IB, Cleton-Jansen AM, Malessy MJ, van der Mey AG, Hogendoorn PC.

Virchows Arch. 2013 Feb;462(2):211-7. doi: 10.1007/s00428-012-1342-8. Epub 2012 Dec 8.

PMID:
23224067
3.

Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.

Borràs E, Jurado I, Hernan I, Gamundi MJ, Dias M, Martí I, Mañé B, Arcusa A, Agúndez JA, Blanca M, Carballo M.

BMC Cancer. 2011 Sep 24;11:406. doi: 10.1186/1471-2407-11-406.

4.

Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours.

Bottillo I, Ahlquist T, Brekke H, Danielsen SA, van den Berg E, Mertens F, Lothe RA, Dallapiccola B.

J Pathol. 2009 Apr;217(5):693-701. doi: 10.1002/path.2494.

PMID:
19142971
5.

Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.

Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR.

Gastroenterology. 2015 Jan;148(1):88-99. doi: 10.1053/j.gastro.2014.09.041. Epub 2014 Oct 8.

6.

Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.

Seth R, Crook S, Ibrahem S, Fadhil W, Jackson D, Ilyas M.

Gut. 2009 Sep;58(9):1234-41. doi: 10.1136/gut.2008.159137. Epub 2009 May 26.

PMID:
19474002
7.

Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.

Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, Liu TC.

Clin Chim Acta. 2012 Oct 9;413(19-20):1605-11. doi: 10.1016/j.cca.2012.04.029. Epub 2012 May 8.

PMID:
22579930
8.
9.

Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer.

Bennani B, Gilles S, Fina F, Nanni I, Ibrahimi SA, Riffi AA, Nejjari C, Benajeh DA, El Abkari M, Martin PM, Ouafik L.

Int J Biol Markers. 2010 Oct-Dec;25(4):179-84.

PMID:
21161938
10.

Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.

Schönleben F, Qiu W, Allendorf JD, Chabot JA, Remotti HE, Su GH.

J Gastrointest Surg. 2009 Aug;13(8):1510-6. doi: 10.1007/s11605-009-0917-4. Epub 2009 May 14.

11.
12.

KRAS and BRAF mutations in Serbian patients with colorectal cancer.

Jakovljevic K, Malisic E, Cavic M, Krivokuca A, Dobricic J, Jankovic R.

J BUON. 2012 Jul-Sep;17(3):575-80.

PMID:
23033302
13.

KRas and BRaf mutational status analysis from formalin-fixed, paraffin-embedded tissues using multiplex polymerase chain reaction-based assay.

Jakubauskas A, Griskevicius L.

Arch Pathol Lab Med. 2010 Apr;134(4):620-4. doi: 10.1043/1543-2165-134.4.620.

PMID:
20367313
14.

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.

Ardighieri L, Zeppernick F, Hannibal CG, Vang R, Cope L, Junge J, Kjaer SK, Kurman RJ, Shih IeM.

J Pathol. 2014 Jan;232(1):16-22. doi: 10.1002/path.4293.

15.

[KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese].

Zhu XL, Cai X, Zhang L, Yang F, Sheng WQ, Lu YM, Du X, Zhou XY.

Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):584-9. doi: 10.3760/cma.j.issn.0529-5807.2012.09.003. Chinese.

PMID:
23157824
16.

Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer.

Ličar A, Cerkovnik P, Novaković S.

Med Oncol. 2011 Dec;28(4):1048-53. doi: 10.1007/s12032-010-9631-z. Epub 2010 Jul 20.

PMID:
20645028
17.

Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.

Cushman-Vokoun AM, Stover DG, Zhao Z, Koehler EA, Berlin JD, Vnencak-Jones CL.

Clin Colorectal Cancer. 2013 Sep;12(3):168-78. doi: 10.1016/j.clcc.2013.04.005. Epub 2013 Jun 14.

18.

Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.

Lamy A, Blanchard F, Le Pessot F, Sesboüé R, Di Fiore F, Bossut J, Fiant E, Frébourg T, Sabourin JC.

Mod Pathol. 2011 Aug;24(8):1090-100. doi: 10.1038/modpathol.2011.60. Epub 2011 Apr 22.

19.

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.

Guedes JG, Veiga I, Rocha P, Pinto P, Pinto C, Pinheiro M, Peixoto A, Fragoso M, Raimundo A, Ferreira P, Machado M, Sousa N, Lopes P, Araújo A, Macedo J, Alves F, Coutinho C, Henrique R, Santos LL, Teixeira MR.

BMC Cancer. 2013 Apr 1;13:169. doi: 10.1186/1471-2407-13-169.

20.

Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.

Zannoni GF, Improta G, Chiarello G, Pettinato A, Petrillo M, Scollo P, Scambia G, Fraggetta F.

Virchows Arch. 2014 Aug;465(2):193-8. doi: 10.1007/s00428-014-1599-1. Epub 2014 Jun 3.

PMID:
24889043

Supplemental Content

Support Center